Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Urd Kielgast"'
Autor:
Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M.J. Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson
Publikováno v:
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5, pp. 14791641221130043 . https://doi.org/10.1177/14791641221130043
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5 . https://doi.org/10.1177/14791641221130043
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5 . https://doi.org/10.1177/14791641221130043
Background The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incid
Autor:
ELISABETH BUUR STOUGAARD, PETER L. KRISTENSEN, URD KIELGAST, SR., HENRIK U. ANDERSEN, YASMIN H. HAMID, PETER GÆDE, ESBEN SØNDERGAARD, GRY DØRFLINGER, KAREN K. FJELDBORG, KLAVS W. HANSEN, HENRIK H. THOMSEN, THURAYA AL-IMARI, MICHAEL RØDER, PETER ROSSING, FREDERIK PERSSON
Publikováno v:
Diabetes. 71
Background: The indication for treatment of type 1 diabetes (T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn from the European market likely because of concern for diabetic ketoacidosis (DKA) . We aime
Autor:
Urd Kielgast, Marianne Lerbæk Bergmann, Simon Veedfald, Caroline C Øhrstrøm, Dorte Worm, Jens J. Holst, Dorte Lindqvist Hansen
Publikováno v:
Øhrstrøm, C C, Hansen, D L, Kielgast, U L, Bergmann, M L, Veedfald, S, Holst, J J & Worm, D 2021, ' Counterregulatory responses to postprandial hypoglycemia after Roux-en-Y gastric bypass ', Surgery for Obesity and Related Diseases, vol. 17, no. 1, pp. 55-63 . https://doi.org/10.1016/j.soard.2020.08.037
Background: Postbariatric hypoglycemia (PBH) is a potentially serious complication after Roux-en-Y gastric bypass (RYGB), and impaired counterregulatory hormone responses have been suggested to contribute to the condition. Objectives: We evaluated co
Publikováno v:
Obesity Surgery. 30:1038-1045
Early dumping and post-bariatric hypoglycemia (PBH) are often addressed as two separate postprandial complications after Roux-en-Y gastric bypass (RYGB). The aim of the study was to evaluate the occurrence of early dumping in RYGB-operated individual
Autor:
Tina Vilsbøll, D.L. Hansen, Asger Lund, Casper K. Nielsen, Caroline Oehrstroem, Urd Kielgast, Filip K. Knop
Publikováno v:
Diabetes. 69
Introduction: Postprandial hypoglycemia is a frequent and debilitating complication following Roux-en-Y gastric bypass (RYGB) without effective treatments. In a proof-of-concept study, we investigated the effects of dasiglucagon, a novel, stable gluc
Autor:
Dorte Lindqvist Hansen, Jens J. Holst, Dorte Worm, Bolette Hartmann, Caroline C Øhrstrøm, Urd Kielgast
Publikováno v:
Obesity surgery. 30(4)
Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150
Publikováno v:
Diabetes. 68
Introduction: Early dumping (ED) and postprandial hypoglycemia (PH) are often addressed as two separate complications after Roux-en-Y gastric bypass (RYGB) although symptoms overlap. We investigated the occurrence of ED in RYGB-patients with PH and p
Autor:
Thure Krarup, Jens J. Holst, Thomas F. Dejgaard, Christian Seerup Frandsen, Henrik U. Andersen, Sten Madsbad, Birger Thorsteinsson, Urd Kielgast
Publikováno v:
Diabetes. 68
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion in adults with type 1 diabetes and residual beta-cell function. This randomized, double-blind, placebo-controlled, 52-week trial evaluated the efficacy of liraglutide 1.8 mg QD added to ins
Autor:
Dorte Lindqvist Hansen, Anna Højager, Ditte Caroline Andersen, Caroline C Øhrstrøm, Urd Kielgast, Jens J. Holst, Dorte Worm
Publikováno v:
Diabetes, obesitymetabolism. 21(9)
AIM To investigate the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide on post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass. MATERIALS AND METHODS In a randomized crossover study, 11 women who had undergone Ro
Autor:
Kirsten Nørgaard, Urd Kielgast
Publikováno v:
Diabetes Therapy
Introduction To estimate lifetime prevalence of diabetes-related upper limb and non-acquired skin manifestations in a representative type 1 diabetes (T1D) population and to identify associations between these conditions and quality of life. Methods A